Law Debenture NAV falls 0.6% in October, underperforming benchmark
Bitget2026/11/12 16:25- Law Debenture's net asset value fell 0.6% in October 2026, trailing the FTSE All-Share benchmark's 1.1% gain.
- Industrial holdings, underweight positions in Shell and AstraZeneca, and exposure to AI-linked energy companies weighed on relative performance.
- Year-to-date NAV total return with debt at fair value reached 14.4%, versus the benchmark's 11.1%.
- The share price stood at 1,172p on October 30, a 2.89% discount to NAV.
- Healthcare positions in Roche and Becton Dickinson were sold, with proceeds partly reinvested in AstraZeneca and GSK.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Full Statement from Nvidia Regarding Jensen Huang's Resignation and Leadership Team Restructuring
On the 12th, the board of directors announced that Jensen Huang has resigned from his positions as President, CEO, and board member, effective immediately. Current Executive Vice President and CFO Colette Kress has agreed to serve as interim CEO. The board has initiated a formal search for a new CEO and will consider candidates both inside and outside the company. At the same time, the board has appointed Harvey C. Jones as its first-ever Chairman.
Crypto prices
More
